• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Combination trametinib and dabrafenib show fewer side effects for metastatic melanoma than dabrafenib alone

byShirin BajajandAdam Whittington
July 31, 2015
in Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients undergoing treatment for metastatic melanoma, there was a statistically significant decreased risk of cutaneous toxic effects in those patients who were treated with combination trametinib and dabrafenib (CombiDT) as compared to dabrafenib alone.

Evidence Rating Level: 2 (Good)

Study Rundown: In the last decade, multiple new medications were created that have vastly improved the prognosis of patients with late-stage melanoma. Namely, BRAF inhibitors dabrafenib and vemurafenib, as well as MEK inhibitors such as trametinib, all have shown a survival benefit. Furthermore, a combination formulation of these drugs, CombiDT, showed superior survival benefit. There has been some evidence that as compared to monotherapy CombiDT also decreases the risk of adverse cutaneous side effects. Authors in this study confirmed this via direct comparison of patients with monotherapy vs. CombiDT. This study was the first of its kind to directly prove these findings, though the findings are limited by the retrospective study design.

Click to read the study in JAMA Dermatology

Relevant Reading: Multiple BRAF Wild-Type Melanomas during Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma

In-Depth [retrospective cohort]: One hundred and eighty five patients with unresectable stage IIIC and IV melanoma who were treated with BRAF inhibitors vemurafenib (n=36), dabrafenib (n=119), or CombiDT (n=30) therapy were selected retrospectively for inclusion. There were no statistically significant differences in treatment duration between treatment groups, although those patients treated with vemurafenib monotherapy were significantly older than those treated with dabrafenib (60 vs. 53 years old, p=0.045). The most common cutaneous adverse effect in patients while on monotherapy with dabrafenib or vemurafenib was Grover disease (51 patients [42.9%] and 14 [38.9%], respectively [P = .67]), plantar hyperkeratosis (47 [39.5%] and 14 [38.9%], respectively [P = .95]), verrucal keratosis (79 [66.4%] and 26 [72.2%], respectively [P = .51]), and cutaneous squamous cell carcinoma (31 [26.1%] and 13 [36.1%], respectively [P = .54]). As compared to dabrafenib, CombiDT therapy showed a statistically significant decrease in cutaneous squamous cell carcinoma (0 vs 31 [26.1%]; P < .001), verrucal keratosis (0 vs 79 [66.4%]; P < .001), and Grover disease (0 vs 51 [42.9%]; P < .001), albeit a higher frequency of folliculitis (12 patients [40.0%] vs 8 [6.7%]; P < .001).

RELATED REPORTS

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dabrafenibmelanomatrametinib
Previous Post

Inhibition of apoliprotein lowers triglyceride levels

Next Post

Placebo formulation impacts effectiveness of pain control in osteoarthritis

RelatedReports

Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma

April 28, 2025
“No Evidence of Disease Activity” may be useful goal in multiple sclerosis
Chronic Disease

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

February 24, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
Medicare beneficiaries have a lower rate of delayed melanoma surgeries
Chronic Disease

Adjuvant dabrafenib and trametinib improve survival in stage III melanoma

November 25, 2024
Next Post
Placebo formulation impacts effectiveness of pain control in osteoarthritis

Placebo formulation impacts effectiveness of pain control in osteoarthritis

Uterus transplant recipients report good psychological outcomes

Uterus transplant recipients report good psychological outcomes

Topical analgesia for dyspareunia effective in breast cancer survivors

Topical analgesia for dyspareunia effective in breast cancer survivors

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.